Menu Back toSession-0102-Future-Direction-of-Global-Drug-Development-With-ICH-E17-Guideline-Focusing-on-MRCTs
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
The 7th DIA China Annual Meeting
Session 0102 Future Direction of Global Drug Development With ICH E17 Guideline Focusing on MRCTs
Yoshiaki Uyama, PhD
- Director, Office of Medical Informatics and Epidemiology
- Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Impacts of E17 Guideline for Drug Review and Approval in Taiwan
- Director, Center of Consultation
- Center for Drug Evaluation, Taiwan
Global Drug Development Impact of ICH E17 Guideline_An Industry Perspective
Patrick Brady, PharmD
- Vice President, Regulatory Affairs Head, Regulatory Policy and Intelligence
- Bayer AG Pharmaceuticals, Germany